AHA Coding Clinic® for HCPCS - 2021 Quarter 1; For Your Information
Newly established HCPCS codes for drugs, biologicals and radiopharmaceuticals as of April 1, 2021
HCPCS Level II Code Long Descriptor Effective Date A9592 Copper Cu-64, dotatate, diagnostic, 1 millicurie April 1, 2021 J1427 Injection, Viltolarsen, 10 mg April 1, 2021 J1554 Injection, immune globulin (ASCENIV), 500 mg April 1, 2021 J7402 Mometasone furoate sinus implant, (sinuva), 10 micrograms April 1, 2021 J9037 Injection, belantamab mafodontin-blmf, 0.5 mg April 1, 2021 J9349 Injection, tafasitamab-cxix, 2 mg April 1, 2021 Q2053 Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose April 1, 2021 ...
Subscribe or sign in to view the full article.
Article Overview
This article summarizes a set of newly established HCPCS Level II entries effective April 1, 2021. It is relevant to coders, billing staff, and compliance teams who track drug, biological, and radiopharmaceutical code updates and need to monitor effective-date changes in HCPCS reporting.
Why This Topic Matters
Keeping up with newly established HCPCS Level II codes helps organizations maintain current charge capture and claims reporting for covered drugs, biologics, and radiopharmaceutical products.
What You Will Learn
- Which HCPCS Level II entries were newly established as of the stated effective date.
- What product categories are represented in the update.
- How the article is organized around code listings and effective dates.
- The scope of the HCPCS Level II changes included in this notice.
Who Should Read This
- Medical coders
- Billing specialists
- Revenue cycle staff
- Compliance teams
- Payer policy analysts
- Pharmacy billing staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com